ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
Abstract Background Most melanoma patients with BRAFV600E positive tumors respond well to a combination of BRAF kinase and MEK inhibitors. However, some patients are intrinsically resistant while the majority of patients eventually develop drug resistance to the treatment. For patients insufficientl...
Main Authors: | Giulia Cesi, Geoffroy Walbrecq, Andreas Zimmer, Stephanie Kreis, Claude Haan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-017-0667-y |
Similar Items
-
Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01) -
MEK inhibition and immune responses in advanced melanoma
by: Reinhard Dummer, et al.
Published: (2017-08-01) -
MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01) -
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
by: Jimin Yuan, et al.
Published: (2020-08-01) -
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma
by: Morgan Homan, et al.
Published: (2022-09-01)